Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Bone Marrow Transplantation

• Publication date

  2014-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bmt.2014.193PMID 25222500
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

  2015cited by this paper
• Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.

  2014cited by this paper
• [Social connection: a report of the SFGM-TC on the maintaining social and family connections during Hematopoietic Stem Cell Transplantation].

  2013cited by this paper
• [Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on gonadal failure and fertility].

  2013cited by this paper
• [Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on adrenal insufficiency and osteoporosis].

  2013cited by this paper
• Suivi et prise en charge des troubles endocriniens en post-greffe de cellules souches hématopoïétiques : insuffisance corticotrope et ostéoporose

  2013cited by this paper
• Conduite à tenir devant une réactivation ou une infection à virus respiratoire syncytial, herpèsvirus 6 et adénovirus après allogreffe de cellules souches hématopoïétiques.

  2013cited by this paper
• [Vaccination post hematopoietic stem cell transplantation: which vaccines and when and, how to vaccinate? An SFGM-TC report].

  2013cited by this paper
• [How I manage respiratory syncytial virus, human herpesvirus 6 and adenovirus reactivation or infection after allogeneic stem cell transplantation: a report of the SFGM-TC].

  2013cited by this paper
• [Diagnosis and treatment of CMV and EBV Reactivation as well as Post-transplant Lymphoproliferative Disorders following Allogeneic Stem Cell Transplantation: An SFGM-TC report].

  2013cited by this paper
• Conduite à tenir devant une anomalie biologique découverte lors du bilan pré-don cellules souches hématopoïétiques : sérologie IgM positive pour le cytomégalovirus, le virus d’Epstein-Barr, la toxoplasmose, ou la syphilis

  2013cited by this paper
• [Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on dyslipidemia and thyroid disorders].

  2013cited by this paper
• Suivi et prise en charge des troubles endocriniens en post-greffe de cellules souches hématopoïétiques : dyslipidémie et thyropathie

  2013cited by this paper
• Suivi et prise en charge des troubles endocriniens en post-greffe de cellules souches hématopoïétiques : insuffisance gonadique et fertilité

  2013cited by this paper
• [How to handle unexpected biological abnormalities observed in the pre-donation workup for hematopoietic stem cell transplantation: an SFGM-TC report on pre-transplant cytomegalovirus, Epstein-Barr virus, Toxoplasma gondii, or syphilis IgM positive serology test].

  2013cited by this paper
• Mobilized peripheral blood stem cells compared with bone marrow from HLA‐identical siblings for reduced‐intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT

  2012cited by this paper
• A proportional hazards regression model for the subdistribution with right‐censored and left‐truncated competing risks data

  2011cited by this paper
• Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire

  2010cited by this paper
• Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.

  2009cited by this paper
• A comparison of allografting with autografting for newly diagnosed myeloma.

  2007cited by this paper
• High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

  2007cited by this paper
• Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma

  2007cited by this paper
• Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.

  2006cited by this paper
• CD34?+ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation

  2005cited by this paper
• National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

  2005cited by this paper
• Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials.

  2005cited by this paper
• Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: ‘what is the best recipe?’

  2005cited by this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

  2005cited by this paper
• Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning.

  2005cited by this paper
• Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio

  2003cited by this paper
• Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.

  2002cited by this paper
• A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.

  2002cited by this paper
• Cellular and Clinical Pharmacology of Fludarabine

  2002cited by this paper
• Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study.

  2002cited by this paper
• Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.

  2001cited by this paper
• Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

  2001cited by this paper
• Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells.

  2001cited by this paper
• Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial.

  2000cited by this paper
• Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation.

  2000cited by this paper
• Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.

  2000cited by this paper
• Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation

  1999cited by this paper
• Mixed chimerism: preclinical studies and clinical applications.

  1999cited by this paper
• Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation.

  1999cited by this paper
• Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

  1998cited by this paper
• A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies

  1998cited by this paper
• Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

  1997cited by this paper
• Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women.

  1996cited by this paper
• 1994 Consensus Conference on Acute GVHD Grading.

  1995cited by this paper
• G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft

  1994cited by this paper
• RISK FACTORS FOR ACUTE GRAFT‐VERSUS‐HOST DISEASE IN HISTOCOMPATIBLE DONOR BONE MARROW TRANSPLANTATION

  1991cited by this paper
• The systemic administration of intravenous melphalan.

  1988cited by this paper
• Pharmacokinetics of high dose melphalan

  1983cited by this paper

• Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome

  2019cites this paper
• A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease

  2019cites this paper
• Transplantations from HLA-identical siblings versus 10/10 HLA-matched unrelated donors.

  2016cites this paper